AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · IEX Real-Time Price · USD
4.530
+0.040 (0.89%)
At close: Mar 28, 2024, 4:00 PM
4.608
+0.078 (1.72%)
After-hours: Mar 28, 2024, 7:08 PM EDT
AbCellera Biologics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for AbCellera Biologics stock have an average target of 19, with a low estimate of 6.00 and a high estimate of 28. The average target predicts an increase of 319.43% from the current stock price of 4.53.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 21, 2024.
Analyst Ratings
The average analyst rating for ABCL stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 2 | 2 | 3 | 3 |
Buy | 5 | 5 | 6 | 6 | 5 | 3 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 8 | 8 | 8 | 8 | 8 | 6 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Benchmark | Benchmark | Hold → Strong Buy Upgrades n/a | Hold → Strong Buy | Upgrades | n/a | n/a | Feb 22, 2024 |
Stifel | Stifel | Strong Buy Maintains $21 → $17 | Strong Buy | Maintains | $21 → $17 | +275.28% | Feb 21, 2024 |
Keybanc | Keybanc | Buy Initiates $6 | Buy | Initiates | $6 | +32.45% | Dec 5, 2023 |
Piper Sandler | Piper Sandler | Buy Initiates $20 | Buy | Initiates | $20 | +341.50% | Oct 13, 2023 |
Benchmark | Benchmark | Strong Buy Maintains $20 → $12 | Strong Buy | Maintains | $20 → $12 | +164.90% | Aug 31, 2023 |
Financial Forecast
Revenue This Year
48.79M
from 38.03M
Increased by 28.30%
Revenue Next Year
69.79M
from 48.79M
Increased by 43.05%
EPS This Year
-0.60
from -0.51
EPS Next Year
-0.62
from -0.60
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 81.3M | 123.8M | 159.3M | 231.4M | 335.0M |
Avg | 48.8M | 69.8M | 83.0M | 136.0M | 182.6M |
Low | 36.2M | 45.5M | 48.8M | 70.6M | 85.3M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 113.9% | 153.7% | 128.2% | 178.8% | 146.4% |
Avg | 28.3% | 43.1% | 18.9% | 63.8% | 34.3% |
Low | -4.9% | -6.8% | -30.1% | -15.0% | -37.3% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -0.25 | -0.14 | -0.47 | -0.22 | 0.09 |
Avg | -0.60 | -0.62 | -0.75 | -0.21 | 0.09 |
Low | -0.99 | -0.97 | -0.99 | -0.21 | 0.09 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.